Compare · CTKB vs RVTY
CTKB vs RVTY
Side-by-side comparison of Cytek Biosciences Inc. (CTKB) and Revvity Inc. (RVTY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CTKB and RVTY operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- RVTY is the larger of the two at $14.10B, about 23.7x CTKB ($594.0M).
- CTKB has been more active in the news (14 items in the past 4 weeks vs 6 for RVTY).
- RVTY has more recent analyst coverage (20 ratings vs 13 for CTKB).
- Company
- Cytek Biosciences Inc.
- Revvity Inc.
- Price
- -
- -
- Market cap
- $594.0M
- $14.10B
- 1M return
- +2.69%
- -
- 1Y return
- +11.84%
- -
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 14
- 6
- Recent ratings
- 13
- 20
Latest CTKB
- Cytek Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure
- Jury Finds in Cytek’s Favor on Three of Four Asserted Claims; Company to Challenge Remaining Finding
- PRESIDENT AND CEO Jiang Wenbin converted options into 120,095 shares and covered exercise/tax liability with 36,269 shares, increasing direct ownership by 2% to 5,561,029 units (SEC Form 4) (for withholding tax)
- Chief Financial Officer Mccombe William D. converted options into 35,420 shares and covered exercise/tax liability with 11,904 shares, increasing direct ownership by 21% to 134,693 units (SEC Form 4) to satisfy withholding tax
- Director Muir Glenn P converted options into 3,086 shares (SEC Form 4)
- Director Holder Michael converted options into 2,181 shares, increasing direct ownership by 4% to 62,875 units (SEC Form 4)
- Director Chin Richard converted options into 6,107 shares, increasing direct ownership by 27% to 28,499 units (SEC Form 4)
- CHIEF TECHNOLOGY OFFICER Yan Ming converted options into 33,270 shares and covered exercise/tax liability with 8,088 shares, increasing direct ownership by 0.52% to 4,821,870 units (SEC Form 4) (tax withholding)
- SEC Form 4 filed by Chief Legal Officer, Secretary Feuchtwang Ilan
- Amendment: SEC Form SCHEDULE 13G/A filed by Cytek Biosciences Inc.
Latest RVTY
- Director Michas Alexis P gifted 285 shares (SEC Form 4)
- Officer Goldberg Joel S gifted 27,785 shares and received a gift of 27,785 shares, decreasing direct ownership by 67% to 13,729 units (SEC Form 4)
- Officer Singh Prahlad R. gifted 67,286 shares and received a gift of 67,286 shares, decreasing direct ownership by 59% to 46,026 units (SEC Form 4)
- SEC Form 10-Q filed by Revvity Inc.
- Revvity Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
- Revvity Announces Financial Results for the Second Quarter of 2026
- Revvity Board Declares Quarterly Dividend
- Vice President and CAO Gonzales Anita sold $9,306 worth of shares (85 units at $109.48) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 7,201 units (SEC Form 4)
- Revvity Releases 2026 Impact Report Advancing Transparency with Initial Scope 3 Emissions Disclosure
- Revvity to Hold Earnings Call on Tuesday, August 4, 2026